Cerezyme will probably lose market share in cost-sensitive regions. I still expect it to keep at least 70% longer term in two-drug market, and at least 50% in three-drug market.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.